By Iain Gilbert
Date: Thursday 07 Aug 2025
(Sharecast News) - Drugmaker Hikma Pharmaceuticals said on Thursday that it was on track to meet FY expectations, with solid top-line growth and strong demand across its portfolio helping offset margin pressures and a drop in operating profits.
Hikma said group revenue had risen 6% to $1.66bn in the six months...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news